- Hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer (BC) is more prevalent in male patients compared to female counterparts.
- Gender associated differences along with molecular differences, immune system, and other factors might play a crucial role in disease management.
- Here, we characterized molecular and immune differences between HR+/HER2- MaBC and FeBC.
Publications
Molecular landscape of HR+/HER2- male breast cancer (MaBC) compared with female breast cancer (FeBC)
– Caris Life Sciences